Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $98.5 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 40.59% year-over-year to $98.5 million in Q1 2026; TTM through Mar 2026 was $507.2 million, a 30.74% decrease from a year earlier, with the FY2025 full-year figure at $574.5 million, down 17.98% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $98.5 million, down from $123.9 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for XENE reached as high as $235.7 million in Q2 2024 and fell as low as $20.3 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $136.6 million across 5 years, with a median of $136.9 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments plunged 55.87% in 2022 and soared 674.7% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $104.8 million in 2022, then surged by 30.66% to $136.9 million in 2023, then increased by 21.01% to $165.6 million in 2024, then slipped by 25.19% to $123.9 million in 2025, then retreated by 20.51% to $98.5 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $98.5 million in Q1 2026, $123.9 million in Q4 2025, and $113.5 million in Q3 2025.